Drug, bio-affecting and body treating compositions inventions 08/07

20070203087 - Chondroitin sulfate synthesis promoter: The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains, as an active ingredient, chondroitin sulfate glucuronyltransferase protein and/or chondroitin sulfate N-acetylgalactosaminyltransferase-1 protein, or a gene encoding the enzyme protein(s).... Agent: Factor & Lake, Ltd

20070203089 - Compositions and methods for the treatment of ophthalmic disease: Compositions and methods of treating ocular disorders comprising CXCR4 inhibitory compositions.... Agent: Allergan, Inc.

20070203056 - novel antiproliferative factor and methods of use: A novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed.... Agent: Fulbright & Jaworski, LLP

20070203055 - Compounds and compositions for prevention of overdose of oxycodone: The invention relates to pharmaceutical compounds and compositions comprised of a chemical moiety attached to an opioid such as oxycodone in a manner that substantially decreases the potential of the opioid to cause overdose. When delivered at the proper dosage the pharmaceutical composition provides therapeutic activity similar to that of... Agent: Hunton & Williams LLP Intellectual Property Department

20070203054 - Fragments of nkp44 for targeting viral-infected and tumor cells: The present invention relates generally to peptides derived from the natural cytotoxicity receptors on natural killer (NK) cells and to antibodies against peptide epitopes on these receptors. In particular, the present invention identifies an essential epitope in the proximal domain of NKp46 and NKp44 receptors present on NK cells, as... Agent: Heslin Rothenberg Farley & Mesiti PC

20070203057 - Compounds and methods for modulating adhesion molecule function: Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof that specifically binds to such a motif. Modulating agents may additionally comprise one or more cell adhesion... Agent: Seed Intellectual Property Law Group PLLC

20070203070 - 28 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070203061 - Adiponectin expression-inducing agents and uses thereof: The present invention provides adiponectin expression-inducing agents, and therapeutic agents using the same for obesity and obesity-related diseases such as cardiovascular diseases or metabolic diseases, as well as methods of searching for adiponectin expression-inducing agents. KLF9, which can bind to the 32-bp fragment of position −188 to position −157 from... Agent: Hunton & Williams LLP Intellectual Property Department

20070203060 - Casein derived peptides and therapeutic uses thereof: Biologically active peptides that are derived from or are similar to sequences of the alphaS1-, alphaS2-, beta- or kapa-casein fractions of milk casein. These peptides are capable of immune modulation and other therapeutic activities, including but not limited to stimulating and enhancing immune response, protecting against viral infection, normalizing serum... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070203066 - Compositions and methods for inhibiting cellular proliferation: Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise peptide molecules, optionally containing one or more individual peptide chains covalently linked, and optionally modified with polyethylene glycol (PEG). The methods involve... Agent: King & Spalding LLP

20070203062 - Compositions and methods for promoting hemostasis and other physiological activities: Compositions that include nanoscale structured materials or precursors thereof (e.g., self-assembling peptides) are described. The compositions can include other substances (e.g., a vasoconstrictor). Also described are methods for using the compositions to promote hemostasis, to protect the skin or wounds from contamination, to decontaminate a site upon removal of previously... Agent: Fish & Richardson PC

20070203069 - Grf-containing lyophilized pharmaceutical compositions: Human growth hormone factor (GFR) containing pharmaceutical compositions are described, and more precisely, lyophilized compositions of hGRF stabilized by means of saccharose.... Agent: Dickstein Shapiro LLP

20070203065 - Insulin-independent, bone morphogenetic protein (bmp)-mediated uptake of blood glucose by peripheral cells and tissues: Methods and compositions comprising a bone morphogenetic protein (BMP) are described for stimulating uptake of serum glucose by peripheral cells and tissues, for treating type 1 or type 2 diabetes, for controlling exocrine pancreatic function, and for treating pancreatitis by an insulin-independent pathway.... Agent: Leon R Yankwich Yankwich & Associates

20070203058 - Novel glp-1 derivatives: Novel polypeptide derivatives having protracted profile of action. The present invention relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via a hydrophilic spacer. The present invention also relates to a compound which comprises a therapeutic polypeptide linked to an albumin binding residue via... Agent: Novo Nordisk, Inc. Patent Department

20070203063 - Pharmaceutical compositions including variants of vascular endothelial cell growth factor having altererd pharmacological properties: Described herein are pharmaceutical compositions including vascular endothelial cell growth factor (VEGF) variants having modifications in the C-terminal heparin binding domain. The variants exhibit reduced clearance rates for systemic administration generally at lower doses compared with native VEGF thus providing variants having longer availability for therapeutic effect.... Agent: Merchant & Gould PC

20070203068 - Stimulation of beta cell proliferation: The present invention relates to a method for increasing the number and/or the size of beta cells, for stimulating beta cell proliferation and for preventing diabetes. The invention is based on the recognition that GLP-1 acts as a beta cell growth factor. The invention also relates to a method for... Agent: Novo Nordisk, Inc. Patent Department

20070203059 - Targeted drug-formaldehyde conjugates and methods of making and using the same: A method and compositions for detecting autoimmunity to islet glucose-6 phosphatase related protein (IGRP). Detection of IGRP autoantibodies alone, and in combination with other molecules such as the 65-kDa form of glutamate decarboxylase (GAD65), insulin and insulin granule membrane proteins ICA512 (IA-2) and phogrin (IA-2) auto-antigens, provides an effective and... Agent: Sheridan Ross PC

20070203067 - Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties: A therapeutic or prophylactic agent for cancer is disclosed which damages the membrane and kills cancer cells, in particular of the blood-forming system, having membrane protein aggregates which contain several core histones or largely core-like histones and/or their parts. The therapeutic or prophylactic agent contains at least one pure histone... Agent: Bacon & Thomas, PLLC

20070203064 - Tlr3 glycosylation site muteins and methods of use: TLR3 glycosylation site muteins, nucleic acids encoding the muteins, and methods of modulating TLR3 activity in a cell are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20070203071 - Conformationally constrained parthyroid hormone (pth) analogs: The invention provides novel P1R polypeptide antagonists. These antagonists contain amino acid substitutions at selected positions in truncated PTH and PRHrP polypeptides and function by binding selectively to the juxtamembrane (“J”) domain of the receptor. The J domain is the region of the receptor that spans the seven transmembrane domain... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070203072 - Hcv ns-3 serine protease inhibitors: Peptidomimetic compounds are described which inhibit the NS3 protease of the hepatitis C virus (HCV). The compounds have the formula where the variable definitions are as provided in the specification. The compounds comprise a carbocyclic P2 unit in conjunction with a novel linkage to those portions of the inhibitor more... Agent: Scully, Scott, Murphy & Presser, P.C.

20070203073 - Sars and ebola inhibitors and use thereof, and methods for their discovery: The instant invention is drawn to methods useful for the treatment or the prevention of a viral infection. The methods include administering at least one compound that is an inhibitor of cathepsin L to an individual. The methods are particularly useful in individuals infected with, or at risk of infection... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070203074 - Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer: e

20070203076 - Creatine ester pronutrient compounds and formulations: The present invention describes a method for providing creatine to an animal, which includes receiving a creatine ester by the animal. The creatine ester is suitable for being modified by the animal to form creatine.... Agent: Dann, Dorfman, Herrell & Skillman

20070203075 - Novel lactam ring-opening enzyme and use thereof: An enzyme capable of reducing the antibiotic activity (i.e., toxicity) of streptothricin with respect to eukaryotic cells without sacrificing antibiotic activity with respect to prokaryotic cells is provided along with a streptothricin derivative having reduced toxicity with respect to eukaryotic cells while retaining antibiotic activity with respect to prokaryotic cells,... Agent: Hogan & Hartson LLPIPGroup, Columbia Square

20070203077 - Treatment and prophylaxis of sepsis and septic shock: A method and composition for the prophylaxis or treatment of humans or animals for septic shock and sepsis using a mixture of sophorolipids.... Agent: Powell Goldstein LLP

20070203078 - Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle: A method for treating psychiatric disorders associated with the menstrual cycle, such as PMS/PMDD and catamenial epilepsy. Reduced activity of specific subtypes of GABA-A receptors is treated by administering compounds that promote activity of these receptors to restore normal function.... Agent: John P. O'banion O'banion & Ritchey LLP

20070203079 - Methods of using small molecule compounds for neuroprotection: Methods are provided for preventing neurodegeneration and neuronal loss by administering compositions comprising small molecule compounds with the effect of preventing neurodegeneration and neuronal loss. In one aspect of the invention, the methods and compositions are also useful for treating neurodegenerative diseases. Small molecule compounds provide an important treatment option... Agent: King & Spalding LLP

20070203080 - New drug delivery system for crossing the blood brain barrier: New ubiquinol analogs are disclosed, as well as methods of using these compounds to deliver drug moieties to the body.... Agent: Morgan, Lewis & Bockius LLP (sf)

20070203081 - Aminoglycosides as antibiotics: The present invention provides aminoglycosides and pharmaceutical compositions that include the aminoglycosides. The aminoglycosides are useful to treat or prevent infectious diseases (e.g., bacterial infections) in a mammal (e.g., human).... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070203086 - Adenosine therapy via interfering rna: System, including methods and compositions, for treating medical conditions via adenosine therapy with interfering RNA that selectively inhibits adenosine metabolism.... Agent: Kolisch Hartwell, P.C.

20070203088 - Detection and modulation of iaps and naip for the diagnosis and treatment of proliferative disease: Disclosed are diagnostic and prognostic kits for the detection and treatment of proliferative diseases such as ovarian cancer, breast cancer, and lymphoma. Also disclosed are cancer therapeutics utilizing IAP antisense nucleic acids, IAP fragments, and antibodies which specifically bind IAP polypeptides.... Agent: Philip Swain, Phd C/o Gowling Lafleur Henderson

20070203084 - Interfering rna duplex having blunt-ends and 3'-modifications: The present invention relates to double-stranded RNA compounds with at least one blunt end comprising at least one 3′-end of Formula (I): wherein X is O or S R1 and R2 are independently OH, NH2, SH, alkyl, aryl, alkyl-aryl, aryl-alkyl, where alkyl, aryl, alkyl-aryl, aryl-alkyl can be substituted by additional... Agent: Novartis Corporate Intellectual Property

20070203085 - Methods for interfering with fibrosis: Modulation of the of glucocorticoid inducible kinases to restore Connective tissue growth factor activity. Also disclosed are methods and compounds useful for the detection and treatment of fibroproliferative disorders.... Agent: Millen, White, Zelano & Branigan, P.C.

20070203083 - Methods of regulating metabolism and mitochondrial function: The invention relates to novel methods of regulating metabolism and mitochondrial biogenesis. Some aspects of the invention relate to methods of treating or preventing diseases in a patient associated with reduced mitochondrial function, to methods of identifying agents to treat such diseases, and to methods of diagnosing such diseases. Other... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070203082 - Rnai agents for anti-sars coronavirus therapy: The present invention provides compositions and methods that are useful for the treatment of severe acute respiratory syndrome (SARS). More specifically, nucleic acid agents such as siRNA molecules and their analogues that target respiratory infections including SARS coronavirus and their methods of use are described, for clinical treatments of SARS,... Agent: Proskauer Rose LLP

20070203090 - N-pyrazole a2a receptor agonists: e

20070203091 - Methods and therapeutic compositions for improving liver, blood flow and skeletal muscle functions in advanced diseases and aging: Administration of adenosine 5′-triphosphate (ATP) and/or other adenine nucleotides such as adenosine 5′-monophosphate (AMP) and/or adenosine 5′-diphosphate (ADP) and/or adenosine provides significant benefits to liver, blood flow and skeletal muscle functions in humans suffering from advanced diseases or in aging individuals. In a preferred mode, 8 hours of continuous intravenous... Agent: Connolly Bove Lodge & Hutz LLP

20070203093 - Antistress agent: The present invention relates to an antistress agent comprising as an active ingredient a saccharide containing 3-O-α-D-glucopyranosyl-D-glucose as a structural unit. It is an object of the present invention to provide said antistress agent which is free from side effects as a medicine, and can be taken habitually and also... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070203094 - Esters of hyaluronic acid with rhein, process for their preparation and compositions comprising the same: The present invention relates to esters of hyaluronic acid with rhein, more particularly to a compound based on hyaluronic acid, wherein alcohol groups of hyaluronic acid are esterified with rhein, to a process for preparing said ester and to a pharmaceutical composition comprising said ester.... Agent: Clifford W Browning Krieg Devault

20070203095 - Treatment of arthritis and other musculoskeletal disorders with crosslinked hyaluronic acid: A method of treating a subject having a musculoskeletal disorder includes administering to a subject's articular site in need thereof an effective amount of a hyaluronic acid (HA) composition. In one embodiment, the HA composition includes an HA derivative, wherein carboxyl functionalities of the hyaluronic acid derivative are each independently... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070203096 - 9-chloro-15-deoxyprostaglandin derivatives, process for their preparation and their use as medicaments: The present invention relates to 9-chloroprostaglandin derivatives of the general formula I which may be advantageous for the treatment of fertility problems.... Agent: Millen, White, Zelano And Branigan, P.C. C/o Berlex Biosciences

20070203097 - Fluoroquinolone carboxylic acid salt compositions: The invention relates to pharmaceutical compositions that are a solution of a salt formed between a fluoroquinolone and a carboxylic acid, a cyclodextrin, and a pharmaceutically acceptable organic solvent and to methods of treating a condition in an animal by administering to an animal in need thereof the pharmaceutical composition... Agent: Kenyon & Kenyon LLP

20070203098 - Pten inhibitors: The therapeutic use of inhibitors of PTEN activity in the treatment of PTEN-mediated diseases, conditions, and injuries is disclosed.... Agent: Polsinelli Shalton Flanigan Suelthaus PC

20070203099 - Anionically substituted 7-nitroindoline derivatives and their uses: Anionically substituted 7-nitroindoline derivatives are disclosed and their uses as caged compounds from which effector species such as neurotransmitters and amino acids are releasable on irradiation with light.... Agent: Dann, Dorfman, Herrell & Skillman

20070203100 - Immunosuppressant compounds and compositions: The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.... Agent: Genomics Institute Of The Novartis Research Foundation

20070203101 - Pyrazolyl-substituted heterocycles and their use as phytosanitary products: e

20070203102 - Estrogen receptor modulators: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone... Agent: Merck And Co., Inc

20070203103 - Preparation of pharmaceutical salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid: This invention relates to a novel process for making 3-O-(3′,3′-dimethylsuccinyl)betulinic acid (“DSB”). This invention also relates to methods of treating HIV and related diseases using pharmaceutical compositions comprising salt forms of DSB prepared according to the process of the present invention. The invention further relates to dosage forms of pharmaceutical... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20070203104 - Pharmaceutical formulations: An aspect of the present invention provides for a medicament including a solution containing pleconaril or a pharmaceutically acceptable salt thereof, wherein at least one solvent including the solution is a pleconaril-dissolving hydrofluorocarbon.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070203105 - Progesterone receptor modulators:

20070203106 - Method for producing 5alpha-pregnane derivative:

20070203107 - Pharmaceutical compositions: The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3β-hydroxy-17β-aminoandrost-5-ene, 3β-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3α-hydroxy-16α-fluoro-17β-aminoandrost-5-ene, 3β-hydroxy-16β-fluoro-17β-aminoandrost-5-ene, 1α,3β-dihydroxy-4α-fluoroandrost-5-ene-17-one, 1α,3β,17β-trihydroxy-4α-fluoroandrost-5-ene, 1β,3β-dihydroxy-6α-bromoandrost-5-ene, 1α-fluoro-3β,12α-dihydroxyandrost-5-ene-17-one, 1α-fluoro-3β,4α-dihydroxyandrost-5-ene and 4α-fluoro-3β,6α,17β-trihydroxyandrostane.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070203110 - 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations: Polymorphs and pharmaceutical formulations of 17-allylamino-17-demethoxygeldanamycin (17-AAG).... Agent: Kosan Biosciences, Inc

20070203112 - Bladder cancer treatment and methods: Disclosed herein are various bladder cancer treatments and methods. The present disclosure can take advantage of propylene glycol concentrations and/or NAD(P)H:quinone oxidoreductase-1 (NQO1), Cytochrome P450 Oxidoreductase (P450R) and Glucose transporter 1 (Glut-1) protein expression in human transitional cell carcinoma of the bladder to offer individually targeted bladder cancer treatments.... Agent: Kirkpatrick & Lockhart Preston Gates Ellis LLP

20070203109 - Compounds and compositions for treatment of cancer: The present invention relates to the use of a therapeutically effective amount of 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1), in the manufacture of a medicament for the treatment of a cancerous condition.... Agent: Swanson & Bratschun, L.L.C.

20070203108 - Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds: Disclosed are compounds which inhibit β-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits β-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical... Agent: Eli Lilly & Company

20070203111 - Cycloalkylamines as monoamine reuptake inhibitors: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as... Agent: Morgan, Lewis & Bockius LLP (sf)

20070203113 - Use of manzamine compounds in anti-cancer therapeutic regimens: Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070203114 - 7,8,9,10-tetrahydro-imidazo [2,1-a] isochinolines: n

20070203115 - Novel quaternary ammonium compounds: A method for inhibiting ileal bile acid transporter activity in a subject, comprising administering to said subject an effective amount of a compound represented by formula (1):... Agent: Young & Thompson

20070203116 - Dihydrospiro[dibenzo[a,d][7]annulene-5,4'-imidazol] compounds for the inhibition of beta-secretase: m

20070203117 - Novel azabicyclic aryl derivatives: This invention relates to novel azabicyclic aryl derivatives which are found to be cholinergic ligands at the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of... Agent: Birch Stewart Kolasch & Birch

20070203118 - Substituted tetrahydroisoquinolines used in the form of mmp inhibitors, method for the production and use thereof in the form of drugs: i

20070203119 - Combination therapy for the treatment of schizophrenia: The present invention relates to a combination of a NK3 receptor antagonist with a 5HT2A receptor antagonist and/or a D2 receptor antagonist, and the use of the combination in treating schizophrenia and associated conditions.... Agent: Merck And Co., Inc

20070203120 - Sulfonyl substituted 1h-indoles as ligands for the 5-hydroxytryptamine receptors: e

20070203121 - Substituted indole compounds, their preparation and use in medicaments: The present invention relates to substituted indole compounds of general formula (I), a process for their preparation, medicaments comprising substituted indole compounds as well as the use of substituted indole compounds for the preparation medicaments, which are suitable e.g., for the prophylaxis and/or treatment of disorders or diseases that are... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070203122 - Derivatives for modulation of ion channels: Sulfonamide derivatives act as ion channel antagonists. The compositions are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20070203123 - Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease: Novel acetylamino benzoic acid compounds, methods of using and pharmaceutical compositions comprising an acetylamino benzoic acid derivative are disclosed. The methods include methods of treating or preventing a disease ameliorated by modulation of premature translation termination or nonsense-mediated mRNA decay, or ameliorating one or more symptoms associated therewith.... Agent: Jones Day

20070203124 - Therapeutic piperazines: wherein R1, X, Z, n, and m have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of PDE4 function and are useful for improving cognitive function in... Agent: Heller Ehrman LLP

20070203125 - Medicament combinations for the treatment of respiratory diseases: e

20070203126 - Synergistic mixtures of o-phenylphenol and dazomet: Ortho phenylphenol acts synergistically with various other antimicrobial compounds commonly used in industrial applications.... Agent: Beck & Thomas, P.C. Suite 100

20070203127 - Antibacterial agents: Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070203128 - Modulation of pathogenicity: In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an... Agent: Womble Carlyle Sandridge & Rice, PLLC Attn: Patent Docketing 32nd Floor

20070203129 - 2-pyridone derivatives as neutrophil elastase inhibitors and their use: There are provided novel compounds of formula (I), wherein R1, R2, R4, R5, G1, G2, L, Y and n are as defined in the Specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in... Agent: Morgan Lewis & Bockius LLP

20070203130 - Bicyclic derivatives as modulators of voltage gated ion channels: Bicyclic derivatives useful as ion channel antagonists are disclosed herein. The compositions thereof are useful for treating or relieving pain-related conditions.... Agent: Vertex Pharmaceuticals Inc.

20070203131 - Bis-aryl sulfonamides: Compounds are provided that act as potent antagonists of chemokine receptors. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of chemokine receptor-mediated diseases, and as controls in assays for the identification of chemokine antagonists.... Agent: Brinks Hofer Gilson & Lione

20070203132 - Triazole derivatives which inhibit vasopressin antagonistic activity: R3 represents H, methyl, methoxy or chloro; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittlesmerchz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.... Agent: Pfizer Inc

20070203133 - Substituted 5,12-diaza-benzoanthracene analogues: Substituted 5,12-diaza-benzoanthracene analogues are provided, of the Formula (I) wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated... Agent: Edwards Angell Palmer & Dodge LLP

20070203134 - Benzimidazole acetonitriles: The present invention is related to benzimidazole acetonitriles as well as to pharmaceutical formulations containing such benzimidazole acetonitriles of formula (I). Said benzimidazole acetonitriles are useful in the treatment of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type II, inadequate glucose tolerance, insulin resistance, obesity, polycystic ovary... Agent: Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070203135 - Novel fused pyrrolocarbazoles: The present invention relates generally to selected fused pyrrolocarbazoles, including pharmaceutical compositions thereof and methods of treating diseases therewith. The present invention is also directed to intermediates and processes for making these fused pyrrolocarbazoles.... Agent: Woodcock Washburn LLP

20070203136 - Triazolopyridazines as kinase modulators: where R1, R5, R6, R7, R8, and A are as defined herein, the use of such compounds as protein tyrosine kinase modulators, particularly inhibitors of c-Met, and the use of such compounds to reduce or inhibit kinase activity of c-Met in a cell or a subject, and modulate c-Met expression... Agent: Philip S. Johnson Johnson & Johnson

20070203137 - new salt: The present invention relates to a new pharmaceutically acceptable salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing said salt and to the use of said active salt in therapy, and particularly to GSK3 related conditions and disorders.... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070203138 - Novel compounds and compositions as cathepsin s inhibitors: The present invention relates to novel selective cathepsin S inhibitors, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.... Agent: Synnestvedt & Lechner LLP

20070203139 - Aryl glycinamide derivatives and their use as nk1 antagonists and serotonin reuptake inhibitors: Compounds of the following Formula (I) wherein R1 and R2 are independently selected from alkyl or alkenyl or from a heterocyclic ring together with the N to which they are bound, n is 0-2, Ar1 is (substituted) phenyl and Ar1 is (substituted) phenyl, naphthyl or tetralin, further as defined in... Agent: Astra Zeneca Pharmaceuticals Lp Global Intellectual Property

20070203141 - Method for administering birb 796 bs: Disclosed are methods of administering BIRB 796 BS, a p38 MAPK inhibitor, at particular dosages.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070203140 - N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase: The present invention is directed to modulators of indoleamine 2,3-dioxygenase (IDO), as well as pharmaceutical compositions containing the same and methods for the treatment of IDO-associated diseases.... Agent: Fish & Richardson PC

20070203142 - Azaindoles useful as inhibitors of janus kinases: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.... Agent: Vertex Pharmaceuticals Inc.

20070203143 - Protein kinase inhibitors: Compounds that inhibit protein kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.... Agent: Robert Deberardine Abbott Laboratories

20070203144 - Use of memantine and brimonidine to attenuate vitreoretinal vascular endothelial growth factor (vegf) protein levels in animals: Reducing the VEGF level in a patient suffering from an ocular disease or condition which is characterized by elevated VEGF and/or blood retina barrier (BRB) breakdown which comprises treating said patient with an effective amount of a compound selected from the group consisting of memantine, brimonidine and mixtures thereof.... Agent: Allergan, Inc.

20070203145 - Zopiclone resolution: Zopiclone can be effectively resolved, and the S-zopiclone isolated, by the use of L-tartaric acid, D-tartaric acid, (+)-ditoluoyltartaric acid, or (−)-ditoluoyltartaric acid.... Agent: SynthonIPInc

20070203146 - Specific salt, anhydrous and crystalline form of a dihydropteridione derivative: The present invention relates to a specific salt of a dihydropteridione derivative, namely the trihydrochloride salt of the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide, to its crystallisation in the form of an hydrate with water, to a process for the manufacture thereof, and to the use thereof in a pharmaceutical composition.... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070203147 - 2-aminothiazole compounds useful as aspartyl protease inhibitors: The present invention is directed to 2-aminothiazole compounds which are aspartyl protease inhibitors, and are inhibitors of both the beta-secretase enzyme and HIV protease, and that are useful in the treatment of diseases in which the beta-secretase enzyme and HIV are involved, such as Alzheimer's disease, HIV Infection and AIDS.... Agent: Merck And Co., Inc

20070203148 - Haloalkyl carboxamides: e

20070203149 - Ccr5 antagonists useful for treating hiv: as inhibitors of the CCR5 receptors, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, methods of preparing pharmaceutical formulations comprising one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with CCR5 using such compounds or... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070203150 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203151 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203152 - Low hygroscopic aripiprazole drug substance and processes for the preparation thereof: The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the aripiprazole anhydride crystals is stored for an extended period.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070203153 - Compositions and methods for treating thrombocytopenia: The present invention in certain embodiments is directed to a pharmaceutical dosage form comprising a therapeutically effective amount of a first agent that agonizes a human TPO receptor by binding to the rhTPO binding site of the human TPO receptor; and a therapeutically effective amount of a second agent that... Agent: Davidson, Davidson & Kappel, LLC

20070203154 - Therapeutic compounds: wherein R1-R6, X, Y, and B have any of the values described herein, as well as salts of such compounds, compositions comprising such compounds, and therapeutic methods that comprise the administration of such compounds. The compounds are inhibitors of MAO-B enzyme function and are useful for improving cognitive function and... Agent: Heller Ehrman LLP

20070203155 - Compounds and compositions as ppar modulators: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR.... Agent: Genomics Institute Of The Novartis Research Foundation

20070203156 - Oxazole ketones as modulators of fatty acid amide hydrolase: Certain oxazole ketone compounds are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat anxiety, pain, inflammation, sleep disorders, eating... Agent: The Scripps Research Institute

20070203157 - Heterocyclic dihydropyrimidine compounds: r

20070203158 - Fungicidal mixtures:

20070203159 - Purine compounds: The invention provides an antimycobacterial 6-aryl-9-(m- or p-substituted-benzyl) purine and purine analog compounds.... Agent: Bacon & Thomas, PLLC

20070203160 - P38 map kinase inhibitors and methods for using the same: Compounds effective as p38 MAP kinase inhibitors, methods of making the compounds, and methods of using the compounds for treatment of p38 MAP kinase-mediated diseases.... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20070203161 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Foley & Lardner LLP

20070203162 - Compositions and methods for inhibition of the jak pathway: The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.... Agent: Foley & Lardner LLP

20070203163 - Novel treatment of irritable bowel syndrome 1: The present invention relates to the use of metabotropic glutamate receptor 5 (mGluR5) antagonists for the treatment of irritable bowel syndrome (IBS).... Agent: Birch, Stewart, Kolasch & Birch, LLP

20070203165 - Compounds and methods for lowering the abuse potential and extending the duration of action of a drug: The abuse potential of a bioavailable drug such as an opiate analgesic agent is reduced and its duration of action is extended by converting it to a poorly absorbed ester prodrug or other prodrug derivative prior to formulation. Unlike many existing sustained release formulations of active pharmaceutical agents wherein an... Agent: Nastech Pharmaceutical Company Inc

20070203164 - Methods and compositions for bactericide, bacteriostatic and anti-inflammation: The present invention relates to a method for providing bactericide or bacteriostatic, especially for treating disease due to bacterial infection. The method comprising administering a patient in need of such treatment a therapeutically effective amount of a compound of dextromethorphan or naloxone or a pharmaceutically acceptable salt or an analog... Agent: Cohen, Pontani, Lieberman & Pavane

20070203166 - Pharmaceutical and diagnostic compositions containing nanoparticles useful for treating targeted tissues and cells: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.... Agent: Allen R. Kipnes, Esq. Watov & Kipnes, P.C.

20070203167 - 2-(hetero)-aryl substituted tetrahydrochinoline: Compounds of the formula I, in which W, R, R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in Claim 1, can be employed, inter alia, for the treatment of tumours... Agent: Heller Ehrman LLP

20070203171 - Combination of rapamycin and its tetrazole isomers and epimers, methods of making and using the same: Epimers and isomers of tetrazole-containing rapamycin analogs are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of inhibiting cancer, fungal growth, restenosis, post-transplant tissue... Agent: Philip S. Johnson Johnson & Johnson

20070203172 - Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same: Isomers and 42-epimers of rapamycin alkyl ether analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method... Agent: Philip S. Johnson Johnson & Johnson

20070203169 - Isomers and 42-epimers of rapamycin ester analogs, methods of making and using the same: Isomers and 42-epimers of rapamycin ester analogs and pharmaceutically acceptable salts or prodrugs thereof, are immunomodulatory agents and are useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a method of... Agent: Philip S. Johnson Johnson & Johnson

20070203168 - Isomers of rapamycin and 42-epi-rapamycin, methods of making and using the same: 15-C isomers of rapamycin and of 42-C Epi rapamycin, and pharmaceutically acceptable salts or prodrugs thereof are disclosed. These compounds are potential immunomodulatory and anti-inflammatory agents, and may be useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection-... Agent: Philip S. Johnson Johnson & Johnson

20070203170 - Rapamycin analogs containing an antioxidant moiety: A rapamycin analog with an antioxidant moiety or a pharmaceutically acceptable salt or prodrug thereof, is an immunomodulatory agent and is useful in the treatment of restenosis and immune and autoimmune diseases. Also disclosed Are cancer-, fungal growth-, restenosis-, post-transplant tissue rejection- and immune- and autoimmune disease-inhibiting compositions and a... Agent: Philip S. Johnson Johnson & Johnson

20070203173 - Stable formulations, and methods of their preparation and use: Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.... Agent: Morrison & Foerster LLP

20070203174 - Method of treating glaucoma: Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated... Agent: Alcon

20070203175 - Productioin of dolasetron: The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates. Intermediates for preparing Dolasetron according to the invention include 7-alkoxycarbonyl-9-(alkoxycarbonylmethyl)-3-trialkylsilyloxy-9-azabicyclo[3.3.1]nonane compounds (SAN compounds) and endo-9-alkoxycarbonyl-5-trialkylsilyloxy-8-azatricyclo[5.3.1.03,8]undecan-10-one compounds (SQO compounds).... Agent: Kenyon & Kenyon LLP

20070203176 - Crystalline forms of dolasetron base and processes for preparation thereof: The present invention provides crystalline polymorphic forms of Dolasetron base. Also provided are methods of preparing the crystalline polymorphic forms of Dolasetron base.... Agent: Kenyon & Kenyon LLP

20070203177 - Forms of dolasetron mesylate and processes for their preparation: The present invention provides crystalline polymorphic forms of Dolasetron mesylate. Also provided are methods of preparing the crystalline polymorphic forms of Dolasetron mesylate. Further, the crystalline Dolasetron mesylate forms may be used in pharmaceutical compositions.... Agent: Kenyon & Kenyon LLP

20070203178 - Crystalline solvates of apixaban: The present invention generally relates to crystalline dimethyl formamide and formamide solvates of apixaban, designated as Forms DMF-5 and FA-2, which are useful for preparing crystalline apixaban hydrate and neat forms.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070203179 - Azadecalin glucocorticoid receptor modulators: The present invention provides a novel class of azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators.... Agent: Townsend And Townsend And Crew, LLP

20070203180 - Substituted quinoline compounds for use as selective estrogen receptor modulator: The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070203181 - Quinoline derivatives and insecticide comprising thereof as active ingredient: Disclosed are compounds that have excellent insecticidal activity and are usable as agricultural and horticultural insecticides. Compounds represented by formula (I) or agriculturally and horticulturally acceptable acid addition salts thereof have excellent insecticidal activity and are usable as agricultural and horticultural insecticides.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070203182 - Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders: The invention relates to the use of certain alpha-aminoamide derivatives in the treatment of RLS and addictive disorders. The compounds of this invention are able to reduce or even stop the symptoms of RLS and addictive disorders substantially without side effects.... Agent: Young & Thompson

20070203183 - Diaryl piperidines as cb1 modulators: e

20070203184 - Novel indolin-2-one derivatives, their preparation and the pharmaceutical compositions comprising them:

20070203185 - Therapeutical composition containing dentritic cells and use thereof: The present invention relates to a method for the preparation of a therapeutical composition, in particular, the present invention relates to a method for treating dendritic cells with a combination of at least one interferon gamma receptor agonist and at least one toll like receptor 2 and/or TLR 6 agonist... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070203189 - 2-amino-4,5-trisubstituted thiazolyl derivatives: L is optionally substituted phenyl or an optionally substituted monocyclic 5 or 6-membered partially saturated or aromatic heterocycle or a bicyclic partially saturated or aromatic heterocycle; aryl is optionally substituted phenyl; for the manufacture of a medicament for the prevention or the treatment of inflammatory and/or auto-immune diseases mediated through... Agent: Philip S. Johnson Johnson & Johnson

20070203187 - Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof: i

20070203188 - Low molecular weight myc-max inhibitors: Compounds and compositions for interfering with the association of Myc and Max are described herein. These compounds and compositions are useful in methods inhibiting growth or proliferation of a cell. Methods of inhibiting growth or proliferation of a cell are provided, comprising contacting the cell with an amount of a... Agent: Jesse A. Hirshman, Esq.

20070203186 - Pyrazole amide derivatives, compositions containing such compounds and methods of use: Pyrazole amides are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent: Merck And Co., Inc

20070203190 - Hydroxylamines and derivatives for the inhibition of complement activation: Methods for the inhibition of complement activation, for the treatment of complement-mediated pathologies, and for the treatment of drusen-mediated pathologies are disclosed. The methods utilize hydroxylamine compounds and ester derivatives thereof, administered to subjects in effective amounts.... Agent: Woodcock Washburn LLP

20070203191 - Insecticidal n-substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines: N-Substituted (6-haloalkylpyridin-3-yl)alkyl sulfoximines are effective at controlling insects.... Agent: Dow Agrosciences LLC

20070203193 - Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist: S

20070203192 - Saturated and unsaturated 3-pyridyl-benzocycloalkylmethyl-amines for use in treating pain, depression and/or anxiety:

20070203194 - Ion channel modulators: The invention relates to compounds, compositions comprising the compounds, and methods of using the compounds and compound compositions. The compounds, compositions, and methods described herein cab be used for the therapeutic modulation of ion channel function, and treatment of disease and disease symptoms, particularly those mediated by certain calcium channel... Agent: Edwards Angell Palmer & Dodge LLP

20070203196 - Methods of preparing indazole compounds: e

20070203195 - Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals: The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R... Agent: Kenneth S. Wheelock

20070203197 - Phosphodiesterase 4 inhibitors: Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs.... Agent: Millen, White, Zelano & Branigan, P.C.

20070203200 - 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical: (iv) provides a Raman spectrum containing peaks at 3106, 3069, 3002, 2961, 1750, 1718, 1684, 1385, 1335, 1229, 1078, 917, 428 and 349 cm−1 and/or (iv) provides a solid-state nuclear magnetic resonance spectrum containing chemical shifts substantially as set out in Table I; a process for the preparation of such... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070203198 - Pharmaceutical composition: Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.... Agent: Foley And Lardner LLP Suite 500

20070203199 - Pioglitazone salts, such as pioglitazone sulfate, and pharmaceutical compositions and processes using the same: Water-soluble salts of pioglitazone especially pioglitazone sulfate are useful in pharmaceutical applications.... Agent: SynthonIPInc

20070203201 - Substituted anthranilamides for controlling invertebrate pests: t

20070203203 - Composition and method for treating fibrotic diseases: The present invention discloses 5-methyl-1-(substituted phenyl)-2(1H)-pyridones have enhanced anti-fibrotic activities than 5-methyl-1-(non-substituted phenyl)-2(1H)-pyridones. An representative example of 5-methyl-(1-substituted phenyl)-2(1H)-pyridones is 1-(3′-fluorophenyl)-5-methyl-2(1H)-pyridone. Accordingly, there are provided compositions comprising one or more compounds selected from the group consisting of 5-methyl-1-(substituted phenyl)-2(1H)-pyridones and methods of using the same to treat or prevent fibrosis... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070203202 - Methods of reducing adverse events associated with pirfenidone therapy: The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1H)-pyridone) therapy.... Agent: Knobbe Martens Olson & Bear LLP

20070203204 - 2-pyridinylcycloalkylbenzamide derivatives and their use as fungicides: e

20070203205 - Diarylsulfones as 5-ht2a antagonists:

20070203206 - 2-pyrrolidone derivatives and use thereof as factor xa inhibitors:

20070203208 - Agents for combating plant pests:

20070203207 - Heteroaromatic glucokinase activators: 2,3-Di-substituted N-heteroaromatic propionamides with said substitution at the 3-position being a substituted phenyl group and at the 2-position being a methyl cycloalkyl ring, said propionamides being glucokinase activators which increase insulin secretion in the treatment of type II diabetes.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070203209 - Useful indole compounds: Indoles having various activities, including indoles that are CRTH2 are described. The compounds are useful for treating asthma, neuropathic pain, allegic rhinitis and other disorders.... Agent: Fish & Richardson PC

20070203210 - Thiazolyl-benzimidazoles: d

20070203211 - Drug for preventing or treating angiogenic eye diseases: A method for the prevention or treatment of intraocular angiogenic diseases such as proliferative retinopathy, retinal vein occlusion, retinal artery occlusion or age-related macular degeneration, which comprises administering to a mammal (such as a human) in need thereof a pharmaceutically effective amount of an angiotensin II receptor antagonist such as... Agent: Frishauf, Holtz, Goodman & Chick, PC

20070203212 - Method of treating osteoarthritis: This invention relates to combinations, compositions, and methods using or having a substituted dialkyl ether, substituted aryl-alkyl ether, substituted dialkyl thioether, substituted dialkyl ketone, or substituted-alkyl compound, or a pharmaceutically acceptable salt thereof, as an active component for preventing or treating osteoarthritis, preventing or inhibiting cartilage damage, preventing or treating... Agent: Warner-lambert Company

20070203213 - Novel ppar ligands that do not cause fluid retention, edema or congestive heart failure: Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effective amount of a compound sufficient to partially or fully activate peroxisome proliferator activated receptors (PPARs) and partially... Agent: Morrison & Foerster LLP

20070203214 - Synthesis of chromanones: Processes for the preparation of biologically active chromanones are disclosed, including processes for the preparation of intermediates useful in the preparation of the biologically active chromanones. The chromanones and the intermediates disclosed herein may be useful for a variety of therapies, including the treatment of various cancers and the treatment... Agent: Senniger Powers

20070203216 - Method of treating inflammatory diseases: The present invention relates to the use of gaboxadol, or a combination of gaboxadol and one or more anti-inflammatory compounds, for the treatment of an inflammatory disease. The present invention further relates to a pharmaceutical composition comprising gaboxadol and one or more anti-inflammatory compounds. The present invention further relates to... Agent: Darby & Darby P.C.

20070203215 - Methods & compositions for enhancing pharmaceutical treatments: Improved methods are provided for therapeutic and/or preventative treatment to a mammal in which the mammal is protected against the toxicity of active pharmaceutical agents that (i) bind to or are substrates for P-gp, (ii) are taxane analogues, and/or (iii) are inhibitors of tubulin disassembly. Additionally provided are compositions and... Agent: Wilson Sonsini Goodrich & Rosati

20070203217 - Substituted stilbenes and their reactions: The present invention relates to stilbene and quinine compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents... Agent: Dann, Dorfman, Herrell & Skillman

20070203218 - Compounds which potentiate glutamate receptor and uses thereof in medicine: This case discloses compounds of formula (I) wherein R1 is C1-6alkyl, haloC1-6alkyl, C2-6alkenyl, amino, monoC1-4alkylamino or diC1-4alkylamino; R2 and R3, which may be the same or different, are hydrogen, halogen, C1-6alkyl, haloC1-6alkyl, C1-4alkoxy, haloC1-4alkoxy, cyano or amino; each R4, which may be the same or different, is C1-6alkyl, halogen, haloC1-6alkyl,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20070203219 - Production of dolasetron: The present invention provides an improved process for the preparation of Dolasetron salts, in particularly Dolasetron mesylate. Also provided are intermediates for the process and methods of preparing the intermediates.... Agent: Kenyon & Kenyon LLP

20070203220 - Inhibitors of pai-1 for treatment of muscular conditions: This invention describes novel methods of treating muscle damage, muscle wasting, muscle degeneration, muscle atrophy or reduced rates of muscle repair associated with various conditions such as muscular dystrophy, through the use of small-molecule PAI-1 inhibitors.... Agent: Woodcock Washburn LLP/wyeth

20070203222 - Substituted gamma lactams as therapeutic agents: Therapeutic compounds, compositions, medicaments, and methods are disclosed herein.... Agent: Allergan, Inc.

20070203221 - Processes for preparing darifenacin hydrobromide: The invention encompasses processes for the preparation of darifenacin hydrobromide.... Agent: Kenyon & Kenyon LLP

20070203223 - Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors: Disclosed is a novel enantiomeric synthesis ceramide-like inhibitors of UDP-glucose: N-acylsphingosine glucosyltransferase. Also disclosed are novel intermediates formed during the synthesis.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070203224 - Small-molecules for treating cancer and abnormal cell proliferation disorders: Novel compounds and compositions that can be used to bind tubulin, prevent tubulin polymerization, inhibit cell growth, arrest cell cycle, cause cell death, or treat cancer or abnormal cell proliferation disorders. Also disclosed are methods for identifying, synthesizing, and using such compounds.... Agent: Hogan & Hartson L.L.P.

20070203225 - Method of increasing endogenous adiponectin production and leptin production: A formulation for and method of enhancing adiponectin and leptin secretion is disclosed. The method comprises contacting living cells with an inhibitor of the enzyme pyruvate dehydrogenase kinase (PDHK). The PDHK inhibitor causes the cells it contacts to increase adiponectin secretion as well as increasing the production of leptin. The... Agent: Bozicevic, Field & Francis LLP

20070203226 - Calcilytic compounds: Novel calcilytic compounds and methods of using them are provided.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20070203227 - Isoflavan and isoflavene compounds and their use as angiogenesis inhibitors: wherein R1 and R2 independently have the meaning of a hydroxy group, or a group that decreases the metabolism or increases the bioavailability of the compound, and the dotted line means an optional double bond, for the treatment of pathological conditions associated with or dependent on enhanced or abnormal angiogenesis... Agent: Birch Stewart Kolasch & Birch

20070203228 - Method for treating chronic obstructive pulmonary disease: e

20070203229 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity:

20070203230 - Novel tricyclic spiroderivatives as modulators of chemokine receptor activity:

20070203231 - Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion: The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.... Agent: Darby & Darby P.C.

20070203232 - Propargylated aminoindans, processes for preparation, and uses thereof: e

20070203233 - Novel 2-(alpha-n-pentanonyl)benzoates, their preparation and use: The present invention relates to novel compounds 2-(α-n-pentanonyl)benzoates, their preparation method, the pharmaceutical composition containing the same, and their use in preparing the medicament for preventing and treating cardio-cerebral ischemic disease, inhibiting thrombosis and alleviating the disturbance of cardio-cerebral circulation.... Agent: Townsend And Townsend And Crew, LLP

20070203234 - Cell repair and regeneration by suramin and related polysulfonated napthylureas: Disclosed herein are compositions and methods for promoting the repair and regeneration of injured tissues, such as injuries resulting from ischemic damage.... Agent: Needle & Rosenberg, P.C.

20070203238 - Method for preventing or reducing elevated triglyceride levels: The present invention is directed to a novel method for reducing triglyceride levels in an infant. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070203235 - Method for preventing or treating anemia: The present invention is directed to a novel method for preventing or treating anemia in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA to the subject.... Agent: Bristol-myers Squibb Company - Mead Johnson

20070203237 - Method for preventing or treating obesity: The present invention is directed to a novel method for preventing or treating obesity in a subject. The method comprises administration of a therapeutically effective amount of DHA and ARA, alone or in combination with one another, to the subject.... Agent: Richard D. Schmidt Bristol-myers Squibb Company

20070203236 - Novel antagonists of the human fatty acid synthase thioesterase: The present invention provides for compounds of formula (I)-(XIII), as well as pharmaceutically acceptable salts thereof, metabolites thereof, pro-drugs thereof, and pharmaceutical kits that include such compounds. The present invention also provides for the compounds of formula (I)-(XIII) for use in medical therapy or diagnosis. The present invention also provides... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070203240 - Personal care compositions and methods for regulating mammalian hair growth: Personal care composition, comprising a first ingredient selected from the group consisting of α-phenyl butyl nitrone (PBN), PBN doxylcyclohexane radicals, 5,5-dimethyl pyrroline N-oxide (DMPO), α-(4-pyridyl 1-oxide)-N-tert-butylnitrone (POBN), 2,2,6,6-tetramethylpiperidine 1-oxide, 4-hydroxytetramethylpiperidine 1-oxide, and the salts of N-(1-oxido-2,2,6,6-tetramethyl-4-piperidyl)-N,N-dimethyl-N-hydroxyethylammonium, 3,5-dibromo-4-nitrosobenzenesulfonic acid, 2-methyl-2-nitrosopropane, nitrosodisulfonic acid, α-(4-pyridyl-1-oxide)-N-t-butylnitrone, 3,3,5,5-tetramethylpyrroline N-oxide, and 2,4,6-tri-t-butylnitrosobenzene, spin-trapping derivatives thereof, and... Agent: The Procter & Gamble Company Intellectual Property Division - West Bldg.

20070203239 - Compounds for the treatment of an acute injury to the central nervous system: KATP channel closers (KCCs) are useful for the prophylactic and/or therapeutic treatment of a CNS acute damage in a mammal, including a human, because their administration, particularly in the case of glibenclamide, potientates the neuroprotector microglial effect. Therefore, they may be useful in treating the acute phase of CNS diseases... Agent: Trask Britt

20070203241 - Antiviral treatments: The invention provides unit dosage forms, kits, and methods useful for treating viral infections.... Agent: Viksnins Harris & Padys Pllp

20070203242 - Method for treating gastric reflux: Methods and compositions for treating gastric reflux or the pain associated therewith comprising orally administering therapeutically effective amounts of a compound or composition capable of releasing nitric oxide in a pharmaceutically acceptable composition are described herein.... Agent: Gary Calton

20070203243 - Resolution of alpha-(phenoxy) phenylacetic acid derivatives: t

20070203244 - Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus: Provided herein are compositions and methods for inhibiting the transmigration of T cells through pancreatic capillary endothelium and treating insulin-dependent diabetes mellitus (IDDM; type I diabetes) using inhibitors of MT1-MMP.... Agent: Needle & Rosenberg, P.C.

20070203245 - Abca1 elevating compounds: The present invention provides compounds useful for increasing cellular ATP binding cassette transporter ABCA1 production in mammals, and to methods of using such compounds in the treatment of coronary artery diseases, dyslipidiemias and metabolic syndrome. The invention also relates to methods for the preparation of such compounds, and to pharmaceutical... Agent: Cv Therapeutics, Inc.

20070203246 - Combinations of cholesterol ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications: The present invention provides combinations of cardiovascular therapeutic compounds for the prophylaxis or treatment of cardiovascular disease including hypercholesterolemia, atherosclerosis, or hyperlipidemia. Combinations disclosed include an HMG CoA reductase inhibitor combined with a cholesteryl ester transfer protein (CETP) inhibitor.... Agent: Pfizer Inc.

20070203248 - Cardioprotective agents: The invention relates to pharmaceutical compositions comprising 5-Methoxytryptamine or a salt thereof for the prevention and/or treatment of mammalian cardiac tissue damage. 5-Methoxytryptamine and the salts thereof act as free radical scavengers in the prevention and/or treatment of mammalian cardiac tissue damage mediated by free oxygen radicals.... Agent: Ladas & Parry

20070203247 - Epinephrine dosing regimens: The present invention relates to methods for administering a first dose of epinephrine solution and an optional second dose of epinephrine solution. Also provided herein are kits useful in these methods.... Agent: Wilson Sonsini Goodrich & Rosati

20070203249 - Method for treating cancer: This invention relates to a process of treating/affecting cancers that are particularly susceptible to radiation therapy by administering to a host in need of such treatment an amino acid and radiation therapy.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070197429 - Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides: According to the present invention, there is provided a range of new conotoxin derivatives and methods for synthesizing these analogues and other intramolecular dicarba bridge-containing peptides, including dicarba-disulfide bridge-containing peptides.... Agent: Fish & Richardson PC

20070197442 - Methods for the treatment of macular degeneration and related eye conditions: The invention provides a peptide-lipid complex for treating age-related macular degeneration and related conditions. The compositions and methods of the instant invention encompass a novel approach to the treatment of age-related macular degeneration and related conditions. Pharmaceutical compositions for this use are also provided.... Agent: Pharmacia & Upjohn

20070197440 - Therapeutic preparation of very high purity fviia and method for obtaining same: The therapeutic preparation of FVIIa having a purity of at least 1000 IU/mg of protein is characterized in that said preparation is free of proteins of non-human origin. In the method for obtaining FVII, purification starts from FrII+III, FrIII or equivalent of Cohn fractioning and comprises precipitation with PEG, chromatography... Agent: Darby & Darby P.C.

20070197444 - Phage displayed cell binding peptides: e

20070197446 - Mhc binding peptides and their uses: The present invention is concerned with MHC binding peptides derived from the avian influenza virus H5N1 and in particular MHC class I restricted binding peptides from the Haemagglutinin 5 (H5) protein from this virus and their uses.... Agent: Ked & Associates, LLP

20070197452 - Treatment of amyloid-related diseases: e

20070197455 - Processes for the convergent synthesis of calicheamicin derivatives: This invention describes processes for the convergent synthesis of calicheamicin derivatives, and similar analogs using bifunctional and trifunctional linker intermediates.... Agent: Wyeth Patent Law Group

20070197478 - Novel pharmaceuticals: The present invention relates to immune response modifiers of formula (I), which act selectively through agonism, of Toll-Like Receptors (TLRs), uses thereof, processes for the preparation thereof, intermediates used in the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including the... Agent: Pfizer Inc

20070197424 - Glatiramer acetate for use as an immuno-modulatory agent: A method for the treatment of hepatic fibrotic injuries caused by various diseases, viral infections or toxic agents which involves the use of glatiramer acetate as an immuno-modulatory agent. The diseases to be treated are hepatic fibrosis and hepatic cellular carcinomas. Also disclose is the use of glatiramer acetate in... Agent: Fleit Kain Gibbons Gutman Bongini & Bianco

20070197425 - Combinations of chromium with antidiabetics for glucose metabolism disorders: Compositions and methods of using the same for the treatment of diabetes and other disorders of glucose metabolism are provided. Compositions may include an anti-diabetic agent and one or more of a bioavailable source of chromium and vanadium.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070197426 - Lactoferrin polypeptide, process for producing the same and inflammation inducing substance: To provide lactoferrin polypeptides which have inducing activity for production of various inflammatory cytokines and various chemokines. Lactoferrin polypeptides characterized by comprising the amino acid sequence of phenylalanine (F), lysine (K) and aspartic acid (D). They are obtained by digestion with proteases. Molecular weights of them are less than 25... Agent: Young & Thompson

20070197427 - O,o'-amidomalonate and n,o-amidomalonate platinum complexes: The present invention relates to amidomalonate O,O′—Pt and N,O—Pt chelates and methods of preparing them in essentially pure form.... Agent: Foley & Lardner LLP

20070197428 - Novel indications of mannan-binding lectin (mbl) in the treatment of immuno-compromised individuals: The present invention relates to the use of a composition comprising at least one mannan-binding lectin (MBL) subunit, or at least one mannan-binding lectin (MBL) oligomer comprising the at least one mannan-binding lectin (MBL) subunit, in the manufacture of a medicament for p